Parecoxib
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Parecoxib: From Postoperative Pain to Migraine Disorder
(Note: the Evidence Pack does not record an original indication for Parecoxib — original_indications is empty. “Postoperative pain” reflects Parecoxib’s publicly known approved use as an injectable COX-2 inhibitor prodrug of valdecoxib; it is not sourced from this Evidence Pack and should be verified against the official SmPC.)
One-Sentence Summary
Parecoxib is a parenteral, selective COX-2 inhibitor (prodrug of valdecoxib); its original approved indication is not captured in this Evidence Pack, and it currently holds 0 marketing authorisations in Denmark (“Not Marketed”). The TxGNN model predicts it may be effective for Migraine Disorder with a prediction score of 99.55%, but this top-ranked candidate has no directly linked clinical trials or literature of its own — supporting evidence is indirect, drawn from a closely related “Headache Disorder” cluster (same TxGNN score family, one pilot RCT).
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not documented in Evidence Pack (general knowledge: short-term treatment of postoperative pain) |
| Predicted New Indication | Migraine Disorder |
| TxGNN Prediction Score | 99.55% |
| Evidence Level | L3 (per pack scoring; based on indirect evidence, not direct trials/literature for this entity) |
| Denmark Market Status | Not Marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data for Parecoxib is not available in this Evidence Pack (blocking/high-severity data gap: DG002). Based on general pharmacological knowledge, Parecoxib is a selective COX-2 inhibitor administered parenterally and rapidly hydrolysed in vivo to its active metabolite, valdecoxib. COX-2 inhibition reduces prostaglandin E2 (PGE2) production, which is the mechanism underlying its established analgesic use.
Migraine pathophysiology involves neurogenic inflammation and meningeal vasodilation, processes partly mediated by the COX-2/PGE2 pathway. Theoretically, COX-2 inhibition could reduce PGE2-induced vasodilation and pain sensitization, complementing triptans (which act on 5-HT1B/1D receptors to cause vasoconstriction). This rationale is documented in the repurposing evidence for the closely related “Headache Disorder” candidate (same disease-entity family, TxGNN score 0.9955), where a pilot RCT (PMID 21996647) directly compared parecoxib to sumatriptan and rizatriptan in acute migraine attacks.
Importantly, this specific “Migraine Disorder” entry has zero directly linked clinical trials or literature — the mechanistic case rests on indirect linkage to the neighboring “Headache Disorder” cluster, not on evidence generated for migraine itself.
Clinical Trial Evidence
Currently no related clinical trials registered.
Indirect note: the related “Headache Disorder” candidate lists 3 trials (NCT01930318, NCT03823846, NCT06623513), all graded “C” relevance — none target migraine/headache directly; they involve postoperative or periprocedural pain settings.
Literature Evidence
Currently no related literature available.
Indirect note: PMID 21996647 (2011, RCT, Clinical Neuropharmacology, Tier 1) — a pilot study comparing IV parecoxib 40mg, SC sumatriptan, and oral rizatriptan for acute migraine attacks — is linked to the “Headache Disorder” candidate, not directly to this “Migraine Disorder” entry.
Denmark Market Information
Not marketed in Denmark; 0 marketing authorisations currently registered in this Evidence Pack.
Safety Considerations
Please refer to the approved Summary of Product Characteristics (SmPC) for safety information.
(Key warnings, contraindications, and drug interaction data are all flagged as data gaps in this Evidence Pack — DG001 is a Blocking-severity gap: TFDA/label warnings and contraindications are unresolved, which prevents a S1 safety pre-assessment.)
Conclusion and Next Steps
Decision: Hold
Rationale:
- The top-ranked candidate (Migraine Disorder) has no direct clinical trial or literature support of its own; the mechanistic case relies on indirect linkage to a neighboring disease cluster and a single small pilot RCT.
- Parecoxib is not currently marketed in Denmark (0 authorisations), and a Blocking data gap (label warnings/contraindications, DG001) prevents even an initial safety screen.
To proceed, the following is needed:
- Danish/EU SmPC or approved label — warnings and contraindications (resolves DG001, Blocking)
- Confirmed mechanism-of-action documentation and original approved indication (resolves DG002)
- Direct clinical trials or literature evaluating Parecoxib specifically in migraine (not only the adjacent headache-disorder cluster)
- Assessment of route/dosage-form compatibility for acute migraine treatment (Parecoxib’s known formulation is parenteral; suitability for outpatient/self-administered migraine care needs review)
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.